Webinars

Postpartum Hemorrhage and Target-Directed MTP Lessons-Learned

INTERCEPT Fibrinogen Complex: Implementation and Initial Experience
Presented during the AABB Science and Innovation Forum

Watch or Learn More

Postpartum Hemorrhage and Target-Directed MTP Lessons-Learned

Implementing the Use of INTERCEPT Fibrinogen Complex (IFC) in the Pediatric Setting
Presented at the SABM Annual Meeting 2022

Watch or Learn More

Postpartum Hemorrhage and Target-Directed MTP Lessons-Learned

Postpartum Hemorrhage and Target-Directed MTP Lessons-Learned about Fibrinogen Replacement
Presented during the AABB Science and Innovation Forum

Watch or Learn More

UF Health Shands’ Experience to Date with INTERCEPT® Fibrinogen Complex (IFC)

UF Health Shands’ Experience to Date with INTERCEPT® Fibrinogen Complex (IFC)
Presented during the AABB Science and Innovation Forum

Watch or Learn More

Introducing a new cryoprecipitated coagulopathy treatment: INTERCEPT® Fibrinogen Complex

Introducing a new cryoprecipitated coagulopathy treatment: INTERCEPT® Fibrinogen Complex
Presented at the SABM Annual Meeting 2021

Watch or Learn More

Meeting the Ever-Changing Needs of Pediatric MTP

Meeting the Ever-Changing Needs of Pediatric MTP
Presented at the SABM Annual Meeting 2021

Watch or Learn More

INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex:

INDICATIONS FOR USE

• Treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
• Control of bleeding when recombinant and/or specific virally inactivated preparations of factor XIII or von Willebrand factor (vWF) are not available.
• Second-line therapy for von Willebrand disease (vWD).
• Control of uremic bleeding after other treatment modalities have failed.

Limitations of Use: Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used for replacement of factor VIII.

CONTRAINDICATIONS

Contraindicated for preparation of blood components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens.

Contraindicated for preparation of blood components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

WARNINGS AND PRECAUTIONS

Only the INTERCEPT Blood System for Cryoprecipitation is approved for use to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex.

For management of patients with vWD or factor XIII deficiency, Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used if recombinant or specific virally-inactivated factor preparations are available. In emergent situations, if recombinant or specific virally-inactivated factor preparations are not available, Pathogen Reduced Cryoprecipitated Fibrinogen Complex may be administered.